Abstract: The present invention is directed to, in part, fused heteroaryl compounds and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late/persistent sodium current. Methods of treating a disease or condition relating to aberrant function of a sodium ion channel including neurological disorders (e.g., Dravet syndrome, epilepsy), pain, and neuromuscular disorders are also provided herein.

Abstract: The present invention is directed to, in part, compositions or dosage forms comprising fused heteroaryl compounds useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late/persistent sodium current. Methods of treating a disease or condition relating to aberrant function of a sodium ion channel including neurological disorders (e.g., Dravet syndrome, epilepsy), pain, neuromuscular disorders, trigeminal autonomic cephalalgia (TAC), migraine, cranial neuropathy or multiple cranial neuropathy, and cortical spreading depression (CSD) are also provided herein. In another aspect, the present invention provides a method of making ion channel modulators.

Abstract: The present invention is directed to, in part, fused heteroaryl compounds of Formula (II-II): and compositions thereof, useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late/persistent sodium current. Methods of treating a disease or condition relating to aberrant function of a sodium ion channel including neurological disorders (e.g., Dravet syndrome, epilepsy), pain, and neuromuscular disorders are also provided herein.

Abstract: The present invention is directed to, in part, fused heteroaryl compounds and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late/persistent sodium current. Methods of treating a disease or condition relating to aberrant function of a sodium ion channel including neurological disorders (e.g., Dravet syndrome, epilepsy), pain, and neuromuscular disorders are also provided herein.

Abstract: The invention relates to combinations of GABA-A Receptor positive allosteric modulators and NMDA antagonists, NMDA Negative Allosteric Modulators or NMDA partial agonists and methods using such combinations to treat mood disorders, such as depression and anxiety.

Abstract: The present invention relates to methods for the treatment of substance abuse disorder, dyspnea, tinnitus, child and adolescent depression, child and adolescent suicidal ideation and behavior, and child and adolescent anxiety using etifoxine or a pharmaceutically acceptable salt thereof.

Abstract: The invention relates to methods of treating the symptoms of perimenopause or menopause using positive allosteric modulators ?-aminobutyric acid type A (GABA-A PAMs) receptor, including 3?-hydroxy-3?-mnethoxymethyl-21-(1?-imidazolyl)-5?-pregnan-20-one and salts thereof.

Abstract: The invention relates to methods of treating depression with Compound 1 or pharmaceutically acceptable salts thereof. The present disclosure, among other things, provides methods of treating depression by administering a therapeutically effective amount of Compound 1 or a pharmaceutically acceptable salt thereof to a patient in need thereof. In another aspect, the present invention provides methods of treating a mood or affective disorder selected from perimenopause, generalized anxiety disorder, panic disorder, social anxiety disorder, post-traumatic stress disorder, acute stress disorder, specific phobia, and selective mutism by administering a therapeutically effective amount of Compound 1 or a pharmaceutically acceptable salt thereof to a patient in need of thereof.

Abstract: The present invention is directed to, in part, fused heteroaryl compounds and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late/persistent sodium current. Methods of treating a disease or condition relating to aberrant function of a sodium ion channel including neurological disorders (e.g., Dravet syndrome, epilepsy), pain, and neuromuscular disorders are also provided herein.

Abstract: The invention relates to methods of treating depression with Compound 1 or pharmaceutically acceptable salts thereof.

Abstract: The invention relates to methods of treating depression with Compound 1 or pharmaceutically acceptable salts thereof.